$KIDS

Pelizzon David R sold $7.8M of KIDS (indirect holdings)

Pelizzon David R sold 336,831 indirectly-held shares of ORTHOPEDIATRICS CORP (KIDS) at an average of $23.04 ($23.04–$23.10, $7.76M total) across 2 trades over 2026-08-28 to 2026-09-01.

Original reporting
SEC EDGAR · Pelizzon David R
Published Sep 1, 2026, 9:13 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 1, 2026, 10:47 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$KIDS
Bearish
medium confidence
Mentioned
$KIDS
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KIDSBearishLow
01

Why it matters

The disclosed sale may trigger short interest and influence price action in the near term.

02

Market read

Insider sale of $7.8M is a material event for a small‑cap, offering a modest trading cue.

03

What to watch

Potential upcoming capital raise or strategic transaction that prompted the insider to diversify.

Relevance 6/10Novelty 6/10Timing: filing date 2026-09-01

Background

Form 4 filings disclose insider transactions; a director selling millions of dollars of stock is noteworthy.

Company-level read

Ticker impact

$KIDSBearishMedium confidence
Context

Director David Pelizzon sold 336,831 shares for $7.76M, reducing his stake to 6.5M shares.

Expected impact

Potential short-term dip of 2‑4% as market digests the sale.

Evidence & confidence

Sale size is material for a small‑cap and the insider holds a significant ownership percentage.

Market effects

Minimal impact on the orthopedics sector beyond KIDS.

U.S. market only; no broader regional effect.

Low; limited to investors tracking insider activity.

Counterpoint

The sale could be a routine liquidity event, not a negative signal.

Key entities

  • Orthopaedics Corp.

    Ticker KIDS, provider of pediatric orthopedic devices.

  • David R. Pelizzon

    Director and 10% owner of Orthopaedics Corp.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$KIDSMed

OrthoPediatrics Corp. Q2 2026 Earnings Call Summary

OrthoPediatrics reported Q2 2026 progress toward a “financial inflection point,” citing record adjusted EBITDA margins near 10% and a shift toward positive free cash flow. Trauma and Deformity revenue grew 26% on implant share gains and early 3P Hip deployments. Management expects positive free cash flow in H2 2026 and FCF break-even or better for full-year 2026, with conservative timing assumptions for capital placements and international orders.